Proof-of-Concept Study of Pipamperone 15mg Added to Stable Risperidone or Paliperidone Treatment in Chronic Schizophrenic and Schizoaffective Patients With Residual Symptoms: a Phase I/IIa, Randomized, Double-blind, Placebo-controlled Trial of 7 Weeks.
Phase of Trial: Phase I/II
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Pipamperone (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- Sponsors PharmaNeuroBoost
- 16 Aug 2014 According to European Clinical Trials Database record, status changed from active not recruiting to completed.
- 06 Jun 2012 Official Title amended as reported by ClinicalTrials.gov.
- 27 Mar 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.